Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy-Reference-Cited by-同舟云学术

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy

Published:2021-12 Issue:5 Volume:111 Page:1145-1154
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Figura Nicholas B.^ORCID,Robinson Timothy J.,Sim Austin J.,Wang Xuefeng,Cao Biwei,Chavez Julio C.,Shah Bijal D.,Khimani Farhad,Lazaryan Aleksandr,Davila Marco,Bachmeier Christina,Nishihori Taiga,Liu Hien D.,Kim Sungjune,Locke Frederick L.,Jain Michael D.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference31 articles.

1. Chimeric antigen receptor T cells in refractory B-cell lymphomas;Schuster;N Engl J Med,2017

2. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor;Kochenderfer;J Clin Oncol,2015

3. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

4. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

5. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial;Locke;Lancet Oncol,2019

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy;Blood Advances;2024-09-24

2. Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma;Critical Reviews in Oncology/Hematology;2024-09

3. Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy;Frontiers in Oncology;2024-08-19

4. Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma;JAMA Oncology;2024-07-01

5. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects;Critical Reviews in Oncology/Hematology;2024-07